Peptide therapy claims on TikTok: what the science supports

What's this video probably claiming?

Given the creator handle and the peptide category tag, this video is almost certainly walking viewers through some combination of BPC-157, TB-500, CJC-1295, ipamorelin, or GHK-Cu as tools for recovery, anti-aging, or body composition. Creators in this space typically frame these peptides as the next generation of performance optimization, sometimes pairing them with growth hormone secretagogues like MK-677 or ipamorelin for compounding effect. The pitch usually goes one of two ways: either a clinical-sounding breakdown of mechanisms (receptor binding, collagen synthesis, GH pulse stimulation) or a personal-use testimonial dressed up in medical credentialing. With 21.6K views, the video found an audience already primed to hear these claims favorably. That audience deserves a closer look at what the actual data says.

What does the science actually show?

BPC-157 has real mechanistic data, mostly in rodents. Chang et al. (2011, Journal of Physiology and Pharmacology) showed accelerated tendon-to-bone healing in rats at doses around 10 mcg/kg. The problem: no peer-reviewed human RCT exists as of 2024. TB-500, a synthetic fragment of thymosin beta-4, has similar animal data supporting angiogenesis and tissue repair, but again, no completed human clinical trials have been published. CJC-1295 with DAC extends GH half-life and does demonstrably raise IGF-1 in humans. Ionescu et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed IGF-1 increases of 200-300% in healthy adults at doses of 1-2 mg/week. Ipamorelin has cleaner safety data than older GHRPs with fewer cortisol and prolactin side effects in early studies. MK-677 raises GH and IGF-1 but also increases fasting glucose and causes water retention, documented in Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism).

Where does the social media noise diverge from clinical reality?

The gap between TikTok peptide content and clinical reality is significant. First, virtually every peptide being promoted in this category is either unapproved for human use, compounded outside FDA oversight, or both. BPC-157 is not FDA-approved. TB-500 is not FDA-approved. The FDA placed BPC-157 on its list of substances that cannot be compounded under Section 503A in 2023, which is a detail creators almost never mention. Second, the "stacking" culture, combining CJC-1295 with ipamorelin, or adding GHK-Cu to a BPC protocol, has zero controlled human safety data. Third, semax and selank, both nootropic peptides developed in Russia, have even thinner Western clinical literature. Any creator presenting these as clinically validated for cognitive enhancement is working well ahead of the evidence. The anecdotal recovery stories are compelling. They are not data.

What should you actually know?

If you're considering any peptide therapy, the regulatory and quality control picture matters as much as the mechanism claims. Compounded peptides vary substantially in purity and concentration between suppliers. A 2021 study by Cohen et al. in JAMA Internal Medicine found that 39% of compounded drug samples tested contained inaccurate labeled doses. That statistic applies to this category. Some peptides, like CJC-1295 and ipamorelin, have enough human pharmacokinetic data to have a real clinical conversation with a licensed provider. Others, like semax and selank, are essentially being tested in real time on social media followers. MK-677 is technically not a peptide but a small molecule ghrelin mimetic, a distinction that matters for how it's regulated. Any telehealth provider offering these therapies should be running baseline labs, monitoring IGF-1 levels, and documenting informed consent on the limited human evidence. If they're not, that's a problem.